Blog
RSS FeedPosted by Michael Wonder on 25 Mar 2026
ICER launches program to accelerate the consideration of value into drug development programs
25 March 2026 - ICER will leverage its health technology assessment expertise to encourage better evidence development in clinical trial ...
Posted by Michael Wonder on 12 Mar 2026
ICER releases draft evidence report on treatment for narcolepsy
12 March 2026 - Public comment period now open until 7 April 2026; requests to make oral comment during public ...
Posted by Michael Wonder on 09 Mar 2026
ICER to assess treatment for Parkinson’s disease
9 March 2026 - Report will be subject of CTAF meeting in October 2026; draft scoping document open to public ...
Posted by Michael Wonder on 03 Mar 2026
ICER publishes special report on treatment for ulcerative colitis and Crohn’s disease as part of CMS public comment process on Medicare drug price negotiations
3 March 2026 - The ICER today posted a special report on Entyvio (vedolizumab, Takeda) for the treatment of ulcerative ...
Posted by Michael Wonder on 12 Feb 2026
ICER publishes final evidence report on medication for smoking cessation
12 February 2026 - Independent appraisal committee votes reflect a net health benefit for cytisinicline alone, but uncertainty when compared ...
Posted by Michael Wonder on 09 Feb 2026
ICER releases evidence report on therapies for IgA nephropathy
9 February 2026 - All three therapies exhibit net health benefits, but uncertainties remain around the magnitude of long-term improvements ...
Posted by Michael Wonder on 16 Dec 2025
ICER publishes final evidence report on treatments for obesity
16 December 2025 - Independent committee voted unanimously on the positive net health benefit of all three treatments; final report ...
Posted by Michael Wonder on 11 Dec 2025
ICER publishes evidence report on medication for smoking cessation
11 December 2025 - Cytisinicline is effective for smoking cessation; a 12 week course of cytisinicline would be cost effective ...
Posted by Michael Wonder on 11 Dec 2025
ICER releases draft evidence report on therapies for IgA nephropathy
10 December 2025 - Public comment period now open until 14 January 2026; Requests to make oral comment during public ...
Posted by Michael Wonder on 10 Nov 2025
ICER releases draft scope on vaccines for Covid-19
10 November 2025 - Report will be subject of New England CEPAC meeting in June 2026; draft scoping document open ...
Posted by Michael Wonder on 31 Oct 2025
ICER publishes final evidence report on treatment for non-cystic fibrosis bronchiectasis
30 October 2025 - Independent appraisal committee voted unanimously on the positive net health benefit of brensocatib; but current pricing ...
Posted by Michael Wonder on 29 Oct 2025
ICER publishes evidence report on treatments for obesity
29 October 2025 - All three drugs result in substantial weight loss; the therapies are cost effective, but the very ...
Posted by Michael Wonder on 23 Oct 2025
New ICER report shows significant jump in launch prices, exceeding inflation and GDP growth
23 October 2025 - Nearly $1.5 billion could have been saved in one year alone if prices matched ICER value ...
Posted by Michael Wonder on 20 Oct 2025
ICER releases draft evidence report on treatment for smoking cessation
20 October 2025 - Public comment period now open until 17 November 2025; requests to make oral comment during public ...
Posted by Michael Wonder on 17 Oct 2025
ICER to assess treatment for narcolepsy
17 October 2025 - Report will be subject of Midwest CEPAC meeting in May 2026; draft scoping document open to ...